Skip to main content

Table 1 The characteristics of IM patients

From: Fluorescence in situ hybridization is superior for monitoring Epstein Barr viral load in infectious mononucleosis patients

 

MILD

IM-HLH or IM-CAEBV

P-value

(n = 31)

(n = 7)

 

Gender

>o.o5

 male

18(58.1%)

3(42.9%)

 

 female

13(41.9%)

4(57.1%)

 

Age

>o.o5

 0–14

24(77.4%)

5(71.4%)

 

 >14

7(22.6%)

2(28.6%)

 

Leukocyte count

>o.o5

 4 × 109/L

7(22.6%)

2(28.6%)

 

 4–10 × 109/L

8(25.8%)

1(14.3%)

 

 ≥10 × 109/L

16(51.6%)

4(57.1%)

 

 Median(range)

10.85(1.2–43.0)

14.9(1.5–61.0)

 

ALT or AST

>o.o5

 high

27(87.1%)

7(100%)

 

 normal/low

4(12.9%)

0(0%)

 

coagulopathy

>o.o5

 positive

22(74.2%)

6(85.7%)

 

 negative

9(25.8%)

1(14.3%)

 

ferritin high

>o.o5

 high

24(77.4%)

6(85.7%)

 

 normal/low

7(22.6%)

1(14.3%)

 

Triglyceride

>0.05

 high

24(77.4%)

6(85.7%)

 

 normal/low

7(22.6%)

1(14.3%)

 

hepatosplenomegaly

>o.o5

 yes

22(71.0%)

6(85.7%)

 

 no

9(29.0%)

1(14.3%)

 

lymphoadenopathy

  

>o.o5

 yes

24(77.4%)

5(71.4%)

 

 no

7(22.6%)

2(28.6%)

 

Days after onset of disease

<o.o5

 average time

34.8d

119.7d(4/7, 3 decreased)

Â